Similarly, incremental costs for various outcomes were calculated and found to be relatively higher for the addition of the SGLT-2 inhibitors in the range of INR 2 million to INR 14 million, requiring different patient treatment years, except with dapagliflozin where ICERs were lesser for ACD and stroke prevention as per CVD-REAL 2 data, but higher for ACD if considering the DECLARE-TIMI data. The gene discussed is SLC5A2; the disease is stroke disorder.